|
| Home : Medivir: Week 24 Interim Results From TMC435 Hepatitis C Phase 2b ASPIRE Study Presented at EASL |
|
Apr 01
2011 |
Medivir: Week 24 Interim Results From TMC435 Hepatitis C Phase 2b ASPIRE Study Presented at EASL |
|
HUDDINGE, Sweden, April 1, 2011 /PRNewswire-FirstCall/ --
- Results Show Potent Antiviral Efficacy of Once Daily 150 mg TMC435 in
Hepatitis C Patients Who Have Failed Earlier Treatment, Especially in Prior
Null Responders, and Excellent Safety and Tolerability
Medivir AB (OMX: MVIR), t |
|
|
|
| Source:http://www.prnewswire.com/news-releases/medivir-week-24-interim-results-from-tmc435-hepatitis-c-phase-2b-aspire-study-presented-at-easl-119040924.html |
| |
|
Related News
|
» eLandia International and Amper Close Definitive Agreement
» Gates Calls for Limited Role Aiding Libyan Rebels
|
|
|
